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ABSTRACT
Background. Sudden death is frequent in haemodialysis (HD) patients. Both hyperkalaemia and change of plasma
potassium (K) concentrations induced by HD could explain this. The impact of increasing dialysate K by 1 mEq/L on plasma
K concentrations and electrocardiogram (ECG) results before and after HD sessions was studied.
Methods. Patients with pre-dialysis K>5.5 mEq/L were excluded. ECG and K measurements were obtained before and after
the first session of the week for 2 weeks. Then, K in the dialysate was increased (from 1 or 3 to 2 or 4 mEq/L, respectively).
Blood and ECG measurements were repeated after 2 weeks of this change.
Results. Twenty-seven prevalent HD patients were included. As expected, a significant decrease in K concentrations was
observed after the dialysis session, but this decrease was significantly lower after the switch to an increased dialysate K.
The pre-dialysis K concentrations were not different after changing, but post-dialysis K concentrations were higher after
switching (P<0.0001), with a lower incidence of post-dialysis hypokalaemia. Regarding ECG, before switching, the QT
interval (QT) dispersion increased during the session, whereas no difference was observed after switching. One week after
switching, post-dialysis QT dispersion [38 (34–42) ms] was lower than post-dialysis QT dispersion 2 weeks and 1 week
before switching [42 (38–57) ms, P¼0.0004; and 40 (35–50) ms, P¼0.0002].
Conclusions. A simple increase of 1 mEq/L of K in the dialysate is associated with a lower risk of hypokalaemia and a lower
QT dispersion after the dialysis session. Further study is needed to determine if such a strategy is associated with a lower
risk of sudden death.
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INTRODUCTION
Chronic haemodialysis (HD) patients are at higher risk of cardio-
vascular mortality [1–3], sudden death being the largest contribu-
tor [3–18]. Ventricular hypertrophy, anaemia, heart failure or
ischaemic heart disease and electrolyte variations are all
potential substrates for arrhythmia and sudden death [4, 12, 13,
16–19]. Abnormalities of potassium (K) before and after dialysis
session, and rapid changes in K concentrations during the dialy-
sis session have been suggested as a potential cause of arrhyth-
mia [5, 7, 12, 13, 20–22]. Hyperkalaemia before dialysis session is
frequent, dangerous and increases morbidity and mortality [7, 17,
18, 22–30]. Additional data also suggest that pre-dialysis hypoka-
laemia, although less frequent, could be associated with higher
mortality [11, 13, 22, 25, 27, 30–32]. The risk of post-dialysis hypo-
kalaemia is much less well studied and thus its prevalence is not
precisely known [11, 31, 33]. Recent data from an observational
cohort of 3967 Japanese patients showed that post-dialysis hypo-
kalaemia (defined as K concentration <3.5 mEq/L) was seen in
half of the patients; almost all of the patients in that study were
dialysed with a dialysate K of 2 mEq/L [31]. Several authors have
suggested that such hypokalaemia induced by dialysis could trig-
ger arrhythmias, and especially ventricular arrhythmias [5, 21].
The excess occurrence of arrhythmia and sudden death in the
first hours after the dialysis are session has been described and
would be consistent with the role for post-dialysis hypokalaemia
[4–7, 13–15, 17, 34, 35]. In addition, there may be a higher risk of
mortality and sudden death in dialysis patients treated with low
dialysate K [4, 8, 9, 12–15, 17, 18, 25, 28–30, 36, 37]. These observa-
tions suggest the utility of switching from low K dialysate to
higher K dialysate [4, 12, 13, 15, 18, 22, 28, 30]. However, most data
supporting this hypothesis are derived from purely observational
cohorts. Moreover, results from observational studies comparing
mortality according to K dialysate are not uniform, and some
authors showed no association between low K dialysate and mor-
tality [17, 24, 30, 36, 38, 39]. A recent observational Japanese study
showed significant association between post-dialysis K concen-
tration and mortality, but the association was lost after adjust-
ment for pre-dialysis K concentration [31]. The present study
sought to examine the impact of increasing dialysate K both on
plasma K concentrations and electrocardiographic results in HD
patients.
MATERIALS AND METHODS
The current prospective study was performed in the depart-
ment of dialysis at the University Hospital of Liège, Belgium. In
November 2017, nephrologists responsible for the dialysis unit
decided to switch the central distribution of dialysate to higher
dialysate K, i.e. from a dialysate concentration of 1 mEq/L (K1)
to 2 mEq/L (K2), or from 3 mEq/L (K3) to 4 mEq/L (K4). The
patients with the following characteristics were included in the
study: age >18 years old, dialysis vintage of at least 3 months
and ability to understand and sign the informed consent. The
patients with the following characteristics were excluded: dialy-
sate K other than K1 or K3 at the first day of the dialysis week,
pre-dialysis K concentration >5.5 mEq/L in one of the last four
blood tests (routinely sampled the first dialysis day of the week,
every 2 weeks in our centre) in patients dialysed with K1,
patients with a non-sinus rhythm at the time of inclusion and
patients haemodialysed less or more than three times a week.
Two weeks before the dialysate K increases, a resting electrocar-
diogram (ECG) was done on the first dialysis day of the week
just before starting dialysis session and, for practical reasons,
the ECG was repeated within 10 min before the end of the same
dialysis session. At the same time as ECG, blood samples were
drawn for measurement of K, sodium (Na), ionized calcium
(Caþþ), bicarbonates and total magnesium (Mg). All the meas-
urements (ECG and blood samples, both before and after dialy-
sis session) were then repeated during 1 and 2 weeks after
switching to higher dialysate K, and as before, on the first dialy-
sis day of the dialysis week. During the study period of 4 weeks
(two before and two after switching to higher dialysate K), the
dialysate K was modified with no other change in Na, Caþþ,
bicarbonates or Mg prescriptions (dialysate or per os). At the
time of the study, only sodium polystyrene sulphonate
(Kayexalate) was prescribed in our centre, and prescription was
not modified during the study period. In the same view, thera-
pies with potential impact on K (like renin–angiotensin–aldoste-
rone inhibitors or diuretics) or ECG results (like b-blockers) were
not modified.
Both plasma Na and K were measured by indirect potenti-
ometry, Mg by colorimetry (xylidyl blue) and bicarbonates by an
enzymatic method. All these measurements were made on
Cobas 8000 (Roche Diagnostics, Mannheim, Germany). Ionized
Caþþ was measured by specific electrode on Rapidlab (Siemens
Healthineers, Erlangen, Germany). All measurements were
done in the same laboratory (Department of Clinical Chemistry,
University of Liège) accredited for the ISO 15189 Guideline. ECG
was performed with a classical 12-lead ECG, the AT 10 Plus
(Schiller AG, Baar, Switzerland). Basal echocardiographic data
were obtained from electronic medical records in 1 year prior to
the study. The protocol of the study was approved by the Ethics
Committee of our institution ‘Comité d’éthique hospitalo-
facultaire universitaire de Liège’ (number B707201627193). The
study was in accordance with the ethical standards of the
Declaration of Helsinki, and signed written consent was
obtained from each patient.
Statistical analysis
Each patient acts as his own control. Data are expressed as
mean 6 SD when distribution was normal and as median with
interquartile range (quartile 1–3) when not. Normality was
assessed by the Shapiro–Wilk test. Accordingly, the paired sam-
ples t-test or the Wilcoxon was considered. Because the sample
is relatively small and the distribution of K concentrations was
not systematically normal (notably after dialysis session), all
concentrations of K are expressed as median with interquartile
range (quartiles 1–3) in comparison analyses. Head-to-head
comparisons were performed for data before and after the dialy-
sis sessions by Wilcoxon test, and a difference was considered
as significant when P< 0.05. Then pre-dialysis K concentrations
before switching (during 2 weeks) were compared with pre-dial-
ysis concentrations after switching (during 2 weeks) using re-
peated measures analysis of variance (ANOVA). The same type
of comparison was then obtained for post-dialysis concentra-
tions. Finally, the percentages of hyperkalaemia before dialysis
and of hypokalaemia after dialysis were compared before and
after switching, by McNemar test. Hyperkalaemia was defined
as a K concentration >5.1 (the normal upper value in our labora-
tory) or >5.5 mEq/L (the upper value frequently considered in
many observational studies). Hypokalaemia was defined as K
concentration <3.5 (the normal lower value in our laboratory) or
<3.0 mEq/L (a value that could be considered as severe hypoka-
laemia). All concentrations presented here were those obtained
on the first day of the dialysis week (Monday or Tuesday).
Regarding ECG data, the following analyses were considered
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and analysed in the same way as kalaemia (before and after the
dialysis session, then before and after the switching of dialy-
sate, Wilcoxon test and repeated measures ANOVA, respec-
tively): heart rate (HR), PQ interval (PQ), QRS duration (QRS), QT
interval (QT), corrected QT (cQT) interval and dispersion of cQT.
All variables are expressed in ms, except HR which is in beats
per minute (b.p.m.). cQT was calculated with the Bazett formula
[16, 40], and cQT dispersion was defined as the difference be-
tween the maximum and minimum QT interval of the 12-lead
ECG [41]. All ECG studies were read by the same observer (F.K.).
In analyses where we considered four results for each patient
(results from 2 weeks and 1 week before and after switching to
higher K dialysate), we used P< 0.05/6¼ 0.0083 to claim statisti-
cal significance according to Bonferroni correction in pairwise




When the decision to switch to higher K dialysate was made, 76
patients were chronically haemodialysed in our department.
Among them, 49 were not considered in the further analysis be-
cause they were already treated with dialysate K2 (n¼ 15) or K4
(n¼ 1), they were <18 years old (n¼ 1), their dialysis vintage was
<3 months (n¼ 1), they were unable to understand the informed
consent (not speaking French or English or demented, n¼ 3) or
they were dialysed more (n¼ 1) or less (n¼ 1) than three times a
week. Finally, 13 patients were excluded because of persistent
hyperkalaemia unless using a low K1 dialysate prescription.
One additional patient was finally excluded due to problem
with arteriovenous fistula (unpredictable single- or two-needle
dialysis). Among eligible patients (n¼ 39), 12 refused to partici-
pate, leaving 27 patients (five women) with complete data for fi-
nal analysis.
Mean (SD) age was 62.9 6 15.3 years old. Clinical and biologi-
cal characteristics of the population are summarized in Table 1.
Native kidney disease is diabetic nephropathy (n¼ 8), glomeru-
lonephritis (n¼ 6), hypertensive nephropathy (n¼ 2), autosomal
dominant polycystic kidney disease (n¼ 3), toxic nephropathy
(n¼ 1), rhabdomyolysis (n¼ 1), chronic pyelonephritis (n¼ 1) and
unknown (n¼ 5). Among the 27 patients, 6 had a history of car-
diac arrhythmia. Two of them were treated by acenocoumarol
and b-blockers, one by amiodarone and one by amiodarone and
b-blocker.
Effect on plasma K
Before changing the dialysate K, a significant decrease in K con-
centrations was observed after the dialysis session: from 4.45
(4.11–4.85) to 3.10 (2.82–3.50) mEq/L (P< 0.0001) 2 weeks before
switching and from 4.55 (4.20–4.95) to 3.34 (2.81–3.66) mEq/L
(P< 0.0001) 1 week before switching. After changing to a higher
dialysate K, the decrease in plasma K concentration after dialy-
sis remained highly significant: from 4.59 (4.35–4.80) to 3.77
(3.26–4.07) mEq/L (P< 0.0001) 1 week after switching and from
4.80 (4.58–5.12) to 3.70 (3.36–4.25) mEq/L (P< 0.0001) 2 weeks af-
ter switching. However, the decrease observed in K concentra-
tion during dialysis was significantly lower after switching to
higher dialysate K: 0.89 (1.37 to 0.39) mEq/L 1 week after
and 1.14 (1.30 to 0.67) mEq/L 2 weeks after, versus 1.66
(1.96 to 0.75) mEq/L 2 weeks before and 1.34 (1.64 to 0.88)
mEq/L 1 week before (all comparisons between before versus
after switching are significant P< 0.05). The pre-dialysis K con-
centrations during the 4-week period were compared by re-
peated measures of ANOVA. Pairwise comparisons showed
slightly higher concentrations 2 weeks after switching, com-
pared with concentrations before switching, but the difference
did not reach statistical significance (P> 0.0125). Regarding
post-dialysis K concentrations, significant higher concentra-
tions (P< 0.0001) were observed after switching to higher K dial-
ysate (Table 2 and Figure 1).
Before switching, the percentage of post-dialysis K concen-
trations <3.5 and 3 mEq/L was 71 and 38%, respectively. After
Table 1. Clinical and biological characteristics of the participants
(n¼27)
Age, years 62.9 6 15.3
Dry weight, kg 77.3 6 19.1
Dialysis vintage, years 2.31 (1.11–4.67)
Residual renal function (>200 mL), % 67
Dialysis time per session, min 240 (210–240)
Haemodiafiltration, % 59
Diabetes, % 30
Inter-dialytic weight gain, the first week, kg 2.3 6 1.5
Cardiologic history
History of heart failure, % 4
History of cardiac hypertrophy, % 56
History of cardiac arrhythmia, % 22
History of atrial fibrillation, % 11
Left ventricular ejection fraction, % 65 (51–70)
Left ventricular end-diastolic diameter, mm 50 6 6
Left atrium dilatation, % 70
Dialysate composition







Bicarbonate, mEq/L 35 (31–37)
Biological variables
Plasma sodium 139.6 6 2.8
Plasma potassium 4.50 6 0.50
4.45 (4.11–4.85)
Plasma ionized calcium 1.17 (1.15–1.24)
Plasma bicarbonates 22.5 (20.8–23.8)




Magnesium per os 19
Bicarbonates per os 4
Calcium per os 100
Diuretics per os 48
b-blockers per os 48
12-lead ECG variables
Heart rhythm, b.p.m. 71 6 12
PQ, ms 176 (157–193)
QRS, ms 94 (86–111)
QT, ms 412 6 41
cQT, ms 445 6 35
QTc dispersion, ms 38 (31–50)
All plasma concentrations and ECG parameters are those obtained on the first
dialysis day of the week, during the first week of the study (before switching).
RAAS, renin–angiotensin–aldosterone system.
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switching to higher K dialysate, this percentage was 35 and 6%,
respectively, a significant decrease for both (P< 0.0001).
Regarding the risk of pre-dialysis hyperkalaemia, we observed a
percentage of pre-dialysis K concentration >5.1 and 5.5 mEq/L
of 11 and 6%, respectively, before the switch. After switching to
higher K dialysate, the percentages were 17 and 7%, respec-
tively. These percentages were not significantly different before
and after the switch to higher K dialysate.
Effect on other electrolytes
In Table 2, we compared the impact of switching to higher K
dialysate on other biological variables (comparison of pre-
dialysis values before versus after switching and comparison
of post-dialysis values before versus after switching). For
other biological variables considered, we did not find any im-
pact of the change in dialysate K, especially after the dialysis
session.
Effect on ECG results
Pre- and post-dialysis variables were analysed by Wilcoxon test
four times (2 weeks before, 1 week before, 1 week after and 2
weeks after switching to higher dialysate K). The following varia-
bles did not change during the dialysis sessions for the 4 weeks:
HR, PQ and QT (Figure 2). QRS values increased during the dialy-
sis session 2 weeks before the switch [94 (86–111) to 98 (90–122)
ms; P¼ 0.0068], 1 week before switching [90 (83–102) to 96 (90–
124) ms; P¼ 0.0416] and 2 weeks after switching [94 (84–111) to 98
(87–119) ms; P¼ 0.0078]. cQT increased during dialysis 2 weeks
before switching [446 (415–466) to 459 (433–483) ms; P¼ 0.0436]
and 2 weeks after switching [432 (417–464) to 459 (431–502) ms;
P¼ 0.0025]. Two weeks or 1 week before switching, the QT dis-
persion increased during the dialysis session from 38 (31–50) to
42 (38–57) (P¼ 0.005) and from 38 (32–50) to 40 (35–50) (P¼ 0.0001),
respectively, whereas no difference was observed after switching
(Figure 2). Then, evolution of pre-dialysis ECG results was com-
pared by repeated measures ANOVA before and after changing
to higher dialysate K. Pairwise comparisons did not show any
difference in pre-dialysis ECG results for HR, PQ, QRS, QT, cQT
and QT dispersion. The same results were observed in post-
dialysis ECG results, except for QT dispersion. Indeed, 1 week af-
ter switching to higher dialysate K, post-dialysis QT dispersion
[38 (34–42) ms] was lower than post-dialysis QT dispersion 2
weeks and 1 week before switching [42 (38–57) ms, P¼ 0.0004;
and 40 (35–50) ms, P¼ 0.0002, respectively]. Two weeks after
switching to higher dialysate K, post-dialysis QT dispersion [38
(35–44) ms] was not different than post-dialysis QT dispersion 2
weeks and 1 week before switching [42 (38–57) ms, P¼ 0.0169;
and 40 (35–50) ms, P¼ 0.1026, respectively] (Figure 3).
DISCUSSION
The present study shows the impact of switching from lower to
higher dialysate K in 27 HD patients. As expected, we found that
dialysis sessions caused a significant decrease of plasma K con-
centrations. The increase in dialysate K was associated with a
lesser decrease in plasma K concentrations [12, 13, 28, 30, 42–
46], and accordingly with a much lower prevalence of post-
dialysis hypokalaemia, including severe hypokalaemia (plasma
K<3.0 mEq/L in 6 versus 38% of cases). The higher post-dialysis
K concentrations observed with higher dialysate K was accom-
panied by only a modest and non-significant increase in pre-
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prevalence of hyperkalaemia). In parallel with variations of K
concentrations, we also observed that QT dispersion after the
dialysis session was significantly lower after the switch to
higher K dialysate. QT interval reflects the total ventricular
recovery time, and QT dispersion is a direct measure of regional
heterogeneity of myocardial repolarization. QT dispersion is as-
sociated with a higher risk of mortality and arrhythmia both in




















































































































































































































































































































































































































Pre-dialysis QT dispersion Post-dialysis QT dispersion
P=0.005
P=0.0001
FIGURE 2: Comparison of pre- and post-dialysis electrocardiographic variables. Comparison 1 and 2 weeks before switching (upper figures) and 1 and 2 weeks after
switching (lower figures). In box-and-whisker plots, the central box represents the values from the lower to upper quartile (25th–75th percentile), the middle line repre-
sents the median and a line extends from the minimum to the maximum value, excluding ‘outside’ values, which are displayed as separate points (open triangle).
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FIGURE 1: Evolution of K concentrations by repeated measures ANOVA before and after switching to higher K dialysate. Comparison of (A) pre-dialysis concentrations
and (B) post-dialysis concentrations. In box-and-whisker plots, the central box represents the values from the lower to upper quartile (25th–75th percentile), the middle
line represents the median and a line extends from the minimum to the maximum value, excluding ‘outside’ values, which are displayed as separate points (open tri-
angle). Pairwise comparison: significant P-value at 0.0083 (bold results are significant). Grey line represents pairwise comparison between a timing before and after
switching, and black line when comparison between timing both before or after switching.
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The decrease of K concentrations during the dialysis session
was expected [12–14, 28, 30, 42, 43, 54, 55]. Also, data from large
cohorts suggested that patients who were treated with lower K
dialysate had a larger decrease in K concentrations during the
dialysis session and, logically a higher risk of hypokalaemia
[43]. However, in these studies, a substantial variability in post-
dialysis K concentrations was observed, even in groups treated
with the same K dialysate [43]. In our study, the patient was his
own control, and such data are rare in the literature. With this
design, we confirm that a dialysis session with a higher dialy-
sate K is associated with a lower decrease in K level and a lower
risk of post-dialysis hypokalaemia. The price to pay in terms of
pre-dialysis potential hyperkalaemia seems acceptable.
Several authors have also studied the impact of a dialysis
session on ECGs. Results from these observational studies are
quite variable, even if most authors showed a modification of
QTc length and/or QT dispersion [20, 54, 56–62]. The role of K or
K changes on these ECG modifications has only been suggested
by few authors who found associations between modification of
plasma K during the dialysis and the incidence of QT abnormal-
ities [54, 57, 58, 62]. Compared with these studies, our results
are straightforward because they were obtained in the same pa-
tient after a single intervention, i.e. an increase of K in the dialy-
sate. Few studies on the impact of modifying K dialysate
concentrations are available. In 1980, Morrison et al. [21] sug-
gested that a higher K concentration in the dialysate (from 2 to
3.5 mEq/L) could be beneficial to decrease ventricular ectopy as
shown by 24-h Holter monitoring, but it was shown in only four
patients. In 1996, Redaelli et al. [46] compared dialysis with con-
stant K concentration in the dialysate (mean concentration of
2.31 mEq/L) with a K concentration in the dialysate varying
according to the change of plasma K during the dialysis session
in 36 patients who were their own control. In the variable K arm
of the study, the K concentration in the dialysate was 1.5 mEq/L
less than that in the plasma and then diminished progressively
until it reached a concentration of 2.5 mEq/L at the end of the
dialysis session. They showed that premature ventricular com-
plexes detected by Holter monitoring were less frequent during
and after the dialysis with ‘adapted K dialysate concentration’
or ‘K profile’. QTc and QT dispersion were not considered in that
study. These interesting results were, however, not confirmed
in a study with a similar design in 30 patients [63]. In 2005,
Buemi et al. [42] studied 28 patients haemodialysed with K2 dial-
ysate versus a K concentration in the dialysate that was 1 mEq/
L less than the concentration in the plasma and then dimin-
ished progressively until it reached K2 at the end of the dialysis
session. They showed that the dialysis with the dialysate K pro-
file had beneficial effect on QT parameters. In 2008, Mu~noz et al.
studied 12 patients considered at high risk of arrhythmia and
compared 3 weeks of dialysis with a constant K concentration
in the dialysate with 3 weeks of dialysis with K dialysate con-
centration that varied during the session, being higher at the
beginning and lower at the end. They observed a beneficial ef-
fect on the cQT values after dialysis, but no effect on QT disper-
sion [45]. We confirmed and extended the results of these
studies. We confirmed the same positive consequences on ECG
variables, but contrary to previous studies, our intervention was
simpler, being an increase of dialysate K by 1 mEq/L, and did
not require the monitoring of plasma K concentration before
(and during) every dialysis session. We note that similar benefi-
cial effects on QT parameters were observed in studies switch-
ing patients from HD to haemodiafiltration [55] or from low to
high calcium dialysate [64].
Our study must be read in the light of its limitations. First,
the increase in dialysate K was used only in patients without
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FIGURE 3: Evolution of QT dispersion concentrations by repeated measures ANOVA before and after switching to higher K dialysate. Comparison of (A) pre-dialysis QT
dispersion (in milliseconds) and (B) post-dialysis QT dispersion. In box-and-whisker plots, the central box represents the values from the lower to upper quartile (25th–
75th percentile), the middle line represents the median and a line extends from the minimum to the maximum value, excluding ‘outside’ values, which are displayed
as separate points (open triangle). Pairwise comparison: significant P-value at 0.0083 (bold results are significant). Grey line represents pairwise comparison between a
timing before and after switching, and black line when comparison between timing both before or after switching.
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short-term, i.e. only for a 4-week period. It could be argued that
a steady-state in K is possibly not reached after 2 weeks.
Therefore, we retrospectively analysed the three pre-dialysis
plasma K concentrations obtained directly after the end of the
current study (K concentration is determined every 2 weeks in
our centre). Dialysate K was not modified during this period of
time (dialysate K similar to dialysate after switching). These
three pre-dialysis plasma K concentrations were not different
(all P> 0.0083) from those observed before and after switching
[4.79 (4.49–5.07), 4.89 (4.40–5.22), 4.83 (4.52–5.29)]. Moreover, 3
months after the switch, patients were re-analysed. Among the
27 patients, 2 died and 2 were transplanted. Among the 23
remaining, the dialysate K remained stable in all, except three
patients who moved from K4 to K2 prescription. Thirdly, for
practical reasons, we measured plasma K and performed the
ECG just before the end of the dialysis. It is known from kinetic
studies that a post-dialysis rebound occurs after dialysis be-
cause of rapid redistribution of intracellular K [12–14, 43]. If such
a rebound is sufficient to be associated with a concomitant,
then improvement in QT dispersion is actually not known. Also,
we admit that QT dispersion is a surrogate marker for cardiac
arrhythmia and mortality [16, 18, 30, 65]. Lastly, our study
remains limited to 27 patients and our results should be con-
firmed in a larger sample.
These clinical data support the switch to higher K dialysate.
Indeed, such a single and simple switch to higher K concentra-
tion (from K3 to K4 or K1 to K2) is accompanied by a lower
prevalence of severe post-dialysis hypokalaemia, to a higher
post-dialysis concentration of K and to lower QT dispersion on
ECG obtained after the dialysis session. The price to pay for
such a strategy seems to be only a modest increase in pre-
dialysis K concentrations. Further studies are needed to test if
the beneficial short-term effect of switching to higher K dialy-
sate both on K concentration and ECG results is also confirmed
in long-term studies with hard clinical outcomes.
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